HYBRID EVENT: You can participate in person at Baltimore, Maryland, USA or Virtually from your home or work.
Regina Au, Speaker at Vaccine Research Conference
BioMarketing Insight, United States
Title : Why Antimicrobial Resistance is a Global Threat and Its Impact On Everyone

Abstract:

Antimicrobial resistance (AR) is an urgent and major global public health threat, killing at least 1.27 million people worldwide and associated with nearly 5 million deaths in 2019, a report from The Lancet. In the U.S., more than 2.8 million antimicrobial-resistant infections occur each year and more than 35,000 people die each year from these infections, based on the CDC’s 2019 AR Threats report. When a bacterium  such as Clostridioides difficile, which normally is not resistant to antibiotics becomes resistant, it can cause deadly diarrhea.  The U.S. toll of all the threats in the report exceeds 3 million infections and 48,000 deaths.

The estimated national cost to treat infections caused by six multidrug-resistant germs frequently found in the health care settings amounts to more than $4.6 billion annually, according to a CDC study.

The CDC is concerned about the emergence and spread of new forms of resistance and rising resistant infections in the community. Community infections puts more people at risk, makes identifying and containment more difficult, and threatens the ability to protect patients in hospitals.

The AR Threats Report noted that when there is dedicated prevention and infection control efforts in the U.S., deaths from antimicrobial-resistant infections were reduced by 18% overall and by nearly 30% in hospitals. However due to pandemic, all progress was diminished and antimicrobial resistance is rapidly rising again. The pandemic pushed healthcare facilities, health departments, and communities to near breaking points in 2020, making it very hard to maintain the progress made in combating antimicrobial resistance.

Combating this challenge requires a 5 prong approach.  All five approaches need to be incorporated to ensure we preserve the effectiveness of existing treatments and our ability to fight infectious diseases in the future:

1) Appropriate and responsible antibiotic usage;

2) Better hygiene practices;

3) Development of new classes of antibiotics;

4) Global collaboration among healthcare sectors; and

5) Prepared readiness - responding and anticipating trends.

These five prong approach will be addressed in more detail.  Slowing antimicrobial resistance is critical to preserving the effectiveness of existing treatments and ensuring our ability to fight infectious diseases in the future:

Audience Take Away:

  1. Everyone, healthcare, non-healthcare professionals, and industry will learn that Antibiotic resistance (AR) is a critical threat not only to patients but to the community as well
  2. They will also learn the enormous negative impact that it has on everyone
  3. Good hygiene is the easiest and most simplest approach to fighting AR.  However, good hygiene needs to be instilled as a critical daily routine, most plans/protocols are observed when infections are up but then people get complacent about protocols and infections rises again
  4. In this 5 prong approach some can be implemented quickly and easily and some require more long term planning commitment
  5. It will make people more conscious about why these protocols need to be in place and the impact if it is not
  6. If they are doing research, more people need to focus on doing more research in this areas and developing newer classes of antibiotics
  7. Antibiotic resistance is a global problem not an isolated problem
  8. This provides a practical solution to a problem that could simplify or make a designer’s job more efficient
  9. It improves the accuracy of a design, or provide new information to assist in a design problem
  10. Stakeholders will realize that more collaboration is need between pharma/biotech companies, academics, government, private institutions and other countries to solve this global threat

Biography:

Regina Au, CEO at BioMarketing Insight with 20+ years experience in the life science industry.  She helps companies define their target product profile (TPP) to be able to compete in the market and be better in meeting the company's goals. 
Ms. Au was a member of the Advisory Board for Regis College Master of Regulatory and Clinical Research Management Program, an Adjunct Professor at Northeastern University in the Biotechnology Program and currently on the Editorial Board for the International Journal of Clinical Pharmacology & Pharmacotherapy.
She has published over 22 articles in scientific and business journals and given 29 presentations at international conferences.
Regina has a BS in microbiology from the University of Michigan, an MBA in Marketing from the University of Connecticut and a Masters in International Management from Thunderbird, Global School of Management.

Watsapp